Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease resulting from loss-of-function pathogenic variants in ADA2 gene, which might resemble polyarteritis nodosa (PAN). The authors present two pediatric cases of ADA2 deficiency with phenotypic manifestations of PAN, including an unusual presentation with spinal cord ischemia. Also described is an assessment of ADA2 activity and gene expression profiling with description of a previously unreported homozygous variant, c.1226C > A (p.(Pro409His)), detected in a patient with consanguineous parents, confirmed by near-absent ADA2 plasma enzymatic activity. The authors suggest to first obtain enzymatic activity, whenever DADA2 is suspected, before proceeding to genetic testing, due to its excellent cost-effective results. Moreover, physicians must be aware of this monogenic disorder, especially in the case of early-onset PAN-like manifestations, having a family member with similar manifestations or having consanguineous parents suggesting an autosomal recessive inheritance pattern. Given the multi-organ involvement, recognizing the diverse manifestations is a crucial step towards timely diagnosis and management of this potentially fatal but often treatable syndrome.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee C-CR, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920
Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931
Ozen S, Bilginer Y, Deniz Batu E, Taşkıran E, Asuman Özkara H, Ünal S (2019) et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2 subtitle: deficiency of adenosine deaminase 2. J Rheumatol. https://doi.org/10.3899/jrheum.181384
Caorsi R, Penco F, Schena F, Gattorno M (2016) Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J 14(1):51. https://doi.org/10.1186/s12969-016-0111-7
Meyts I, Aksentijevich I (2018 Jul) Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 38(5):569–578. https://doi.org/10.1007/s10875-018-0525-8
Human A, Pagnoux C (2019) Diagnosis and management of ADA2 deficient polyarteritis nodosa. Int J Rheum Dis 22(Suppl 1):69–77
Caorsi R, Omenetti A, Morreale A, Insalaco A, Buoncompagni A, Picco P, Malattia C, Gandolfo C, Aksentievic I, Martini A, Gattorno M (2015) Rapid and sustained effect of anti-TNF treatment in patients with ADA2 deficiency. Pediatr Rheumatol Online J 13(Suppl 1):O80
Ozen S, Pistorio A, Iusan SM et al (2010) Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798–806
Springer JM, Gierer SA, Jiang H, Kleiner D, Deuitch N, Ombrello AK, Grayson PC, Aksentijevich I (2018) Deficiency of adenosine deaminase 2 in adult siblings: many years of a misdiagnosed disease with severe consequences. Front Immunol 9:1361
Lee PY (2018) Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. Front Pediatr 6:282. https://doi.org/10.3389/fped.2018.00282 eCollection 2018
Santo GC, Baldeiras I, Guerreiro R, Ribeiro JA, Cunha R, Youngstein T et al (2018) Adenosine deaminase two and immunoglobulin M accurately differentiate adult Sneddon’s syndrome of unknown cause. Cerebrovasc Dis 46(5–6):257–264. https://doi.org/10.1159/000495794
Keer N, Hershfield M, Caskey T, Unizony S (2016) Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology (Oxford) 55(6):1145–1147. https://doi.org/10.1093/rheumatology/kew050
Ombrello A, Stone D, Hoffmann P, Jones A, Barham B, Barron K et al (2015) The deficiency of adenosine deaminase type 2—results of therapeutic intervention. Pediatr Rheumatol 13(Suppl 1). https://doi.org/10.1186/1546-0096-13-S1-O40
Cagdas D, Gur Cetinkaya P, Karaatmaca B, Esenboga S, Tan C, Yılmaz T, Gümüş E, Barış S, Kuşkonmaz B, Ozgur TT, Bali P, Santisteban I, Orhan D, Yüce A, Cetinkaya D, Boztug K, Hershfield M, Sanal O, Tezcan İ (2018) ADA deficiency: evaluation of the clinical and laboratory features and the outcome. J Clin Immunol 38(4):484–493. https://doi.org/10.1007/s10875-018-0496-9
Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, Conti G et al (2017) ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 76(10):1648–1656. https://doi.org/10.1136/annrheumdis-2016-210802
Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli ET, Ozdogan H, Kasapcopur O (2018) Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int 38(1):129–136. https://doi.org/10.1007/s00296-017-3740-3
Hashem H, Kelly SJ, Ganson NJ, Hershfield MS (2017) Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of polyarteritis nodosa and a mimic of other systemic rheumatologic disorders. Curr Rheumatol Rep 19(11):70. https://doi.org/10.1007/s11926-017-0699-8
Fayand A, Sarrabay G, Belot A, Hentgen V, Kone-Paut I, Grateau G, Melki I, Georgin-Lavialle S (2018) Multiple facets of ADA2 deficiency: vasculitis, auto-inflammatory disease and immunodeficiency: a literature review of 135 cases from literature. Rev Med Interne 39(4):297–306. https://doi.org/10.1016/j.revmed.2017.11.006
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ganhão, S., Loureiro, G.B., Oliveira, D.R. et al. Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review. Clin Rheumatol (2020). https://doi.org/10.1007/s10067-020-05210-4
- Adenosine deaminase 2
- CECR1 gene
- Monogenic vasculitis
- Novel mutation
- Polyarteritis nodosa